AnaptysBio rosnilimab Phase 2b RA data shows best-in-disease profile with JAK-like efficacy

ANAPTYSBIO, INC

424-patient Phase 2b trial: rosnilimab achieved JAK-like efficacy on CDAI LDA, remission, and ACR70 through six months.
Favorable safety: no treatment-related SAEs, <2% discontinuation due to AEs, low injection site reactions.
Responses durable for at least 2 months off drug; pain VAS improved ~50 points from baseline ~65 to ~15.
69% of patients achieved CDAI LDA by Week 14; max response rates not yet observed due to strict continuation criteria.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.